892 related articles for article (PubMed ID: 24055823)
1. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Kochenderfer JN; Dudley ME; Carpenter RO; Kassim SH; Rose JJ; Telford WG; Hakim FT; Halverson DC; Fowler DH; Hardy NM; Mato AR; Hickstein DD; Gea-Banacloche JC; Pavletic SZ; Sportes C; Maric I; Feldman SA; Hansen BG; Wilder JS; Blacklock-Schuver B; Jena B; Bishop MR; Gress RE; Rosenberg SA
Blood; 2013 Dec; 122(25):4129-39. PubMed ID: 24055823
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
Brudno JN; Somerville RP; Shi V; Rose JJ; Halverson DC; Fowler DH; Gea-Banacloche JC; Pavletic SZ; Hickstein DD; Lu TL; Feldman SA; Iwamoto AT; Kurlander R; Maric I; Goy A; Hansen BG; Wilder JS; Blacklock-Schuver B; Hakim FT; Rosenberg SA; Gress RE; Kochenderfer JN
J Clin Oncol; 2016 Apr; 34(10):1112-21. PubMed ID: 26811520
[TBL] [Abstract][Full Text] [Related]
3. Donating used CARs.
Rapoport AP
Blood; 2013 Dec; 122(25):4007-9. PubMed ID: 24335030
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
[TBL] [Abstract][Full Text] [Related]
5. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
6. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.
Jacoby E; Yang Y; Qin H; Chien CD; Kochenderfer JN; Fry TJ
Blood; 2016 Mar; 127(10):1361-70. PubMed ID: 26660684
[TBL] [Abstract][Full Text] [Related]
7. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
Cruz CR; Micklethwaite KP; Savoldo B; Ramos CA; Lam S; Ku S; Diouf O; Liu E; Barrett AJ; Ito S; Shpall EJ; Krance RA; Kamble RT; Carrum G; Hosing CM; Gee AP; Mei Z; Grilley BJ; Heslop HE; Rooney CM; Brenner MK; Bollard CM; Dotti G
Blood; 2013 Oct; 122(17):2965-73. PubMed ID: 24030379
[TBL] [Abstract][Full Text] [Related]
8. Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation.
Tan X; Wang XQ; Zhang C; Zhao XL; Yao H; Chen G; Ma YY; Wen Q; Gao L; Gao L; Kong PY; Shen Y; Zhang X; Lou SF
Curr Med Sci; 2023 Aug; 43(4):733-740. PubMed ID: 37330456
[TBL] [Abstract][Full Text] [Related]
9. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
[TBL] [Abstract][Full Text] [Related]
10. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Kochenderfer JN; Rosenberg SA
Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
[TBL] [Abstract][Full Text] [Related]
11. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
12. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
[TBL] [Abstract][Full Text] [Related]
13. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
14. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Kochenderfer JN; Dudley ME; Feldman SA; Wilson WH; Spaner DE; Maric I; Stetler-Stevenson M; Phan GQ; Hughes MS; Sherry RM; Yang JC; Kammula US; Devillier L; Carpenter R; Nathan DA; Morgan RA; Laurencot C; Rosenberg SA
Blood; 2012 Mar; 119(12):2709-20. PubMed ID: 22160384
[TBL] [Abstract][Full Text] [Related]
15. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
[TBL] [Abstract][Full Text] [Related]
17. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
[TBL] [Abstract][Full Text] [Related]
18. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
20. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
